Metabolism of Chlordiazepoxide in the Treatment of Alcohol Withdrawal Symptoms

Alcohol Withdrawal Clinical Trial

Official title:

Association Between Variations in CYP Pheno- and Genotypes and Plasma Concentration of Chlordiazepoxide in the Treatment of Alcohol Withdrawal Symptoms

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05563350
• Other study ID #: KLOPOXID2021
• Status: Completed
• Start date: January 29, 2022
• Est. completion date: July 1, 2023

Study information

• Verified date: September 2022
• Source: University Hospital Bispebjerg and Frederiksberg
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The aim of this study is to elucidate if CYP-phenotypes, variations in CYP-genotypes and dose of chlordiazepoxide is correlated to chlordiazepoxide plasma concentrations in patients admitted to Intensive Care or High Dependency Units due to either respiratory insufficiency and/or agitation while treated for alcohol withdrawal symptoms.

Description:

Pharmacological treatment caries a risk of overdosing and adverse events. Chlordiazepoxide, among other sedative drugs, has been associated with an increased risk of death. Chlordiazepoxide treatment for alcohol withdrawal symptoms will render some patients in need of ventilatory support and ICU admission. Other patients will not obtain the desired effect from the treatment and will be in a state of agitation despite having received high doses of chlordiazepoxide. This individual variation in effect is not predictable and may be explained by variations in the capacity of drug metabolism. Chlordiazepoxide is extensively metabolized in the liver by hepatic microsomal enzymes and exhibits capacity limited, protein binding sensitive, hepatic clearance. Metabolism is primarily by cytochrome P450 (CYP), especially CYP3A4 and CYP2C19 systems. Evaluation of CYP phenotypes by drug probe phenotyping is extensively used. Midazolam possesses several characteristics that makes it useable as a pharmacological probe for CYP3A activity despite having already received other benzodiazepines. It is metabolized to a primary metabolite exclusively by CYP3A4/3A5.Omeprazole can likewise be used as a pharmacological probe for CYP2C19. The drug of investigation is chlordiazepoxide, which has been given before study inclusion. After inclusion and during the study period (12 hours), it is not allowed to administer chlordiazepoxide to the patient. In case of abstinence, the recommended therapy is diazepam or propofol. Blood samples will be collected and plasma concentrations of chlordiazepoxide and metabolites will be analyzed and compared with the amount of chlordiazepoxide administered at inclusion and 12 hours after inclusion. Independent variables: - Variations in genotypes of CYP3A4/3A5 and CYP2C19. - Phenotypes of CYP3A4/3A5 and CYP2C19, analyzed as above /below the median value of enzyme activity. Variations in genotypes of CYP3A4/3A5 and CYP2C19 will be analyzed from blood samples. Phenotyping of CYP3A4/3A5 and CYP2C19 will be performed with midazolam and omeprazole as pharmacological probes respectively. 2 mg of midazolam and 10 mg of omeprazole will be administered intravenously as bolus within 12 hours after inclusion. Blood samples 2 h after dosing (t=2 h dosing) will be collected and analyzed for plasma concentrations of omeprazole, hydroxyomeprazole, midazolam and 1-hydroxymidazolam. The ratio between omeprazole and hydroxyomeprazole will be used to classify the CYP2C19 phenotype as the ratio between midazolam and 1-hydroxymidazolam will be used in the classification of CYP3A4/3A5 By measuring concentration of chlordiazepoxide and the ability to metabolize chlordiazepoxide in ICU- or HDU-patients with respiratory insufficiency, impaired consciousness or agitation after treatment for alcohol withdrawal symptoms, we will investigate if there is a correlation between the patient's phenotypes of the CYP3A4/3A5 and CYP2C19 systems (independent variable) and the concentration of chlordiazepoxide (primary outcome).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: July 1, 2023
• Est. primary completion date: June 11, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age =18 years
• Treatment with minimum 200 mg chlordiazepoxide for alcohol withdrawal symptoms during hospital admission
• Acute admittance to ICU or HDU due to respiratory insufficiency, impaired consciousness or agitation.
• Inclusion possible within 12 h of ICU/HDU admission.

Exclusion Criteria:

• Allergies to omeprazole/esomeprazole and midazolam
• Treatment with chlordiazepoxide within the first 12 h after inclusion (from blood samples at inclusion until blood samples 12 h after inclusion)
• Treatment with omeprazole/esomeprazole within 1 day prior to ICU/HDU admission and within the first 12 h after inclusion.
• Treatment with midazolam within 1 day prior to ICU/HDU admission
• Cardiac arrest prior to admission
• Pregnancy (a negative hcg (from urine or blood sample) has to be present before inclusion of women aged <50 years)

Related Conditions & MeSH terms

• Alcohol Withdrawal
• Substance Withdrawal Syndrome

Intervention

Diagnostic Test:
• Blood samples
p-chlordiazepoxide and metabolites, p-omeprazole and metabolites, p-midazolam and metabolites, CYP3A4 and CYP2C19 genotyping

Locations

Country	Name	City	State
Denmark	Bispebjerg and Frederiksberg Hospital	Copenhagen

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital Bispebjerg and Frederiksberg

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Plasma concentration of chlordiazepoxide and metabolites	p-chlordiazepoxide and metabolites.	At inclusion and 12 hours after inclusion
Secondary	Half-life (T½) for chlordiazepoxide	Half-life (T½) for chlordiazepoxide will be estimated from the area under the concentration time curve (AUC) from concentrations of chlordiazepoxide at inclusion and 12 hours after inclusion.	At inclusion and 12 hours after inclusion
Secondary	Cumulative dose of chlordiazepoxide before admission to ICU/HDU	Chlordiazepoxide dose in mg	From date of hospital admittance until the date of inclusion in the study no later than 12 hours after admission on either ICU or HDU
Secondary	ICU/HDU and hospital length of stay (LOS) within 90 days	ICU Length of stay and Hospital length of stay	90 days after ICU admission and 90 days after hospital admission
Secondary	Need for mechanical ventilation within 90 days	Duration of treatment with mechanical ventilation	90 days after inclusion